Donor Preoperative Management

Invasive Hemodynamic Monitoring/Initial Management Invasive hemodynamic monitoring is used selectively in donors to assist in optimizing cardiovascular management prior to organ procurement. In the unstable donor it is essential to determine the relative need for volume expansion versus inotropes versus vasopressors, since appropriate therapy will maximize the number of suitable organs. An arterial line is used for close monitoring of all donors. Central venous pressure monitoring is also useful in most cases for monitoring of volume status and for reliable delivery of drugs. A pulmonary artery catheter is used selectively in situations of hemodynamic instability or questionable cardiac function. The ability to distinguish hemodynamic instability caused by inadequate preload (relative hypovolemia) versus inappropriate afterload (peripheral vasomotor collapse) versus depressed inotropic state (cardiac contractile dysfunction) is essential to guide effective donor management.76 The use of a pulmonary artery catheter can be most useful under these circumstances.

A urinary drainage catheter is placed in all potential donors to monitor urinary output, assess renal function, and keep pace with the large urine output seen with diabetes insipidus which occurs in 50-70% of all organ donors. Although not always considered from the outset of the patient's hospital course, placement of a nasogastric tube is critical to help prevent aspiration in all potential lung donors. Early placement of a nasogastric tube should be stressed to all hospitals and organ procurement organizations caring for multi-organ donors.

Intravenous Fluid Management

Following most forms of brain injury but prior to declaration of brain death, intravenous fluid is usually restricted in an attempt to limit cerebral edema and salvage any existing CNS function. This management, along with the nearly universal occurrence of diabetes insipidus due to pituitary nonfunction, may result in profound hypovolemia. Moreover, as part of the pathophysiology of brain death, there is usually a secondary loss of vasomotor tone. Therefore, when a potential donor is first identified, they are frequently intravascularly volume depleted, vasodilated, and hypotensive. Once a potential donor is declared brain dead, the first maneuver in donor management is to accurately assess the intravascular volume status and the peripheral vasomotor tone and then appropriately pursue aggressive volume repletion, with an intravenous fluid infusion ratio equal to the hourly urine output plus 100 mL/hr, maintaining the CVP in the 4-12 cm H2O range. Vasopressin or DDAVP (water soluble form of shorter acting vasopressin) is often required to sustain euvolemia. Close observation and correction of electrolyte abnormalities is required to avoid hypo- or hyperosmolar states which can have deleterious consequences such as tissue damage and dysrhythmias.

While aggressive volume resuscitation may benefit most solid organs, it will often have a detrimental effect on donor lung function. One report has demonstrated that merely raising the CVP from 4-6 cm H2O up to 8-10 cm H2O with crystalloid solution causes a significant increase in the alveolar arterial oxygen gradient.77 The careful use of colloid solutions is recommended whenever possible in an attempt to maintain intravascular volume. Hemodynamic problems related to peripheral vasomotor tone are best managed with pressor agents with the goal of maintaining a normal systemic vascular resistance. With careful attention to volume management, the need for inotropic or pressor support is less common. Sustained or excessive inotropic requirements in the presence of ad

equate filling pressures and peripheral resistance should raise questions about the suitability of the heart for organ procurement.

Blood Products

Blood products are used very judiciously in organ donors due to the risks of transmissible infectious diseases and of sensitizing the recipient to multiple additional other donor antigens. The role of donor specific transfusion and nonspecific transfusion is not completely understood. We prefer to avoid transfusion of all blood products in both the donor and the recipient unless absolutely necessary. We would prefer to transfuse only leuko-reduced blood products when the oxygen carrying capacity of the blood falls too low (Hemoglobin < 8.0 gm% or SVO2 < 60).

Medications

In the donor population, low dose inotropes or pressor agents are often utilized in order to limit the volume of fluid infused (Table 7.4). Additionally, ino-tropic agents can be used as a test to observe the hemodynamic response in a questionable donor. Antiarrhythmic agents are infrequently used, as the more common dysrhythmia would be sinus tachycardia, typically due to hypovolemia. DDAVP (vasopressin), as described above, is commonly used to manage diabetes insipidus. Thyroxine has been used in situations where conventional pressor support is not effective. Support for this practice is controversial in the literature but has been effective in selected clinical settings.78,79

Table 7.4. Frequently utilized medications for donor management

1. Hormonal Agents

Desmopressin (DDAVP) 0.3 mcg/kg IV over 30 min repeat if urine output not controlled maximum total dose-4 mcg

Vasopressin (Pitressin)

5-10 U q8h IV, or continuous infusion 0.5 to 1 U/hour titrate to maintain urine output between 100 and 300 ml/hour

Thyroxine (T4)

20 mcg IV followed by a thyroxine infusion of 200 mcg in 500 mL normal saline at 25 mL/hour titrate to maintain adequate blood pressure

2. Inotropic Agents

Dopamine 3-10 mcg/kg/min

Dobutamine 5-10 mcg/kg/min

Epinephrine 0.01-0.03 mcg/kg/min

3. Pressor Agents

Phenylephrine 0.06-0.18 mg/min

Ventilator Management

After establishing donor status, ventilator management should be directed at limiting barotrauma. A CMV mode is usually appropriate, with a weight proportional tidal volume (10-15 mL/kg). Fraction of inspired oxygen should be maintained at less than or equal to 40%, or sufficient to keep the arterial saturation above 90%. Airway pressures should be in normal range (less than 25 cm H2O), and low levels of PEEP (5 cm H2O) are used to help limit atelectasis. Any changes in lung compliance should be reported to the transplant teams.

Temperature

Abnormalities in thermoregulation are relatively common after brain death, reflecting hypothalamic dysfunction. Treatment of both hypo- and hyperthermia are important to avoid complications such as dysrhythmias and tissue damage. Management of these temperature fluctuations are relatively basic. For hypothermia, application of warming blankets, heating lights, warmed intravenous fluids and ventilator circuit gases are means to maintain body temperature between 36.5°C-37.5°C. Conversely, treatment of hyperthermia includes the use of cooling blankets, ice packs, and alcohol compresses after searching for systemic infection by obtaining blood, urine, and sputum cultures.

References

1. Griepp RB, Stinson EB, Clark DA et al. The cardiac donor. Surg Gynecol Obstet 1971; 133:792-798.

2. Copeland JG. Only optimal donors should be accepted for heart transplantation: Protagonist J Heart Lung Transplant 1995; 14:1038-1042.

3. Todd TR, Goldberg M, Koshal A et al. Separate extraction of cardiac and pulmonary grafts from a single organ donor. Ann Thorac Surg 1988; 46:356-359.

4. Zenati M, Dowling RD, Armitage JM et al. Organ procurement for pulmonary transplantation. Ann Thorac Surg 1989; 48:882-6.

5. Sundaresan S, Trachiotis GD, Aoe M et al. Donor lung procurement: Assessment and operative technique. Ann Thorac Surg 1993; 56:1409-13.

6. Egan TM. Selection and management of the lung donor. In: Patterson GA and Couraud L, ed, Lung Transplantation. Elsevier Science B.V. 1995:103-115.

7. Kauffman HM, Bennett LF, McBride MA et al. The expanded donor. Transplant Rev 1997; 11:165-190.

8. Pflugfelder PW, Singh NR, McKenzie FN et al. Extending cardiac donor ischemic time and donor age: Effects on survival and long-term cardiac function. J Heart Lung Transpl 1991; 10:394-400.

9. Shumway SJ, Hertz MI, Petty MG et al. Liberalization of donor criteria in lung and heart-lung transplantation. Ann Thorac Surg 1994; 57:92-95.

10. Ott GY, Herschberger RE, Ratkovec RR et al. Cardiac allografts from high-risk donors: Excellent clinical results. Ann Thorac Surg 1994; 57:76-82.

11. Livi U, Bortolotti U, Luciani GB et al. Donor shortage in heart transplantation. Is extension of donor age limits justified? J Thorac Cardiovasc Surg 1994; 107:1346-1355.

12. Drinkwater DC, Laks H, Blitz A et al. Outcomes of patients undergoing transplantation with older donor hearts. J Heart Lung Transplant 1996; 15:684-91.

13. Livi U, Caforio ALP, Tursi V et al. Donor age greater than 50 years does not influence midterm results of heart transplantation. Transplant Proc 1996; 28:91-2.

14. Burnett CM, Radovancevic B, Birovljev S et al. Concomitant donor heart coronary artery bypass grafting during orthotopic heart transplantation. Texas Heart Inst J 1990; 17:126-8.

15. Laks H, Gates RN, Ardehali A et al. Orthotopic heart transplantation and concurrent coronary bypass. J Heart Lung Transplant 1993; 12:810-15.

16. Starnes VA, Barr ML, Cohen RG et al. Living-donor lobar lung transplantation experience: Intermediate results. J Thorac Cardiovasc Surg 1996; 112:1284-91.

17. Couetil JPA, Tolan MJ, Loulmet DF et al. Pulmonary bipartitionaing and lobar transplantation: A new approach to donor organ shortage. J Thorac Cardiovasc Surg 1997; 113:529-37.

18. Gundry SR, Alonso de Begona J, Kawauchi M et al. Transplantation and reanimation of hearts removed from donors 30 minutes after warm, asystolic ëdeathi. Arch Surg 1993; 128:989-93.

19. D'Alessandro AM, Hoffman RM, Knechtle SJ et al. Successful extrarenal transplantation from non-heart-beating donors. Transplant 1995; 59:977-82.

20. Buchanan SA, DeLima NF, Binns OA et al. Pulmonary function after non-heart-beating lung donation in a survival model. Ann Thorac Surg 1995; 60:36-48.

21. Cooper DKC. Clinical survey of heart transplantation between ABO blood group-incompatible recipients and donors. J Heart Transplant 1990; 9:376-81.

22. Lanza RP. Effect of ABO blood-group antigens on long-term survival after cardiac transplantation. N Engl J Med 1982; 307:1275-6.

23. Nakatani T, Aida H, Frazier OH et al. Effect of ABO blood type on survival of heart transplant patients treated with cyclosporine. J Heart Lung Transplant 1989; 8:27-33.

24. Shumway SJ, Baumgartner WA, Soule LM et al. Lack of effect of ABO blood-group antigens on survival after cardiac transplantation. N Engl J Med 1987; 317:772-3.

25. Bourge RC, Naftel DC, Costanzo-Nordin MR et al. Pretransplantation risk factors for death after heart transplantation: A multiinstitutional study. J Heart Lung Transplant 1993; 12:549-62.

26. UNOS 1997 Report of Center Specific Graft and Patient Survival Rates. UNOS, Richmond, VA 1997; 88-139.

27. Young JB, Naftel DC, Bourge RC et al. Matching the heart donor and heart transplant recipient. Clues for successful expansion of the donor pool: A multivariable, multiinstitutional study. J Heart Lung Transplant 1994; 13:353-65.

28. Hosenpud JD, Bennett LF, Keck BM et al. The registry of the International Society for Heart and Lung Transplantation: Fourteenth official report, 1997. J Heart Lung Transplant 1997; 16:691-712.

29. Kobashigawa JA, Kirklin JK, Naftel DC et al. Pretransplantation risk factors for acute rejection after heart transplantation: A Multiinstitutional study. J Heart Lung Transplant 1993; 12:355-66.

30. Kubo SH, Naftel DC, Mills RM et al. Risk factors for late recurrent rejection after heart transplantation: A multiinstitutional, multivariable analysis. J Heart Lung Transplant 1995; 14:409-18.

31. Baumgartner WA. Evaluation and management of the heart donor. In: Baumgartner WA, Reitz BA, and Achuff SC, ed, Heart and Heart-Lung Transplantation. WB Saunders Co. 1990:86-102.

Hosenpud JD, Pantely GA, Morton MJ et al. Relation between recipient:donor body size match and hemodynamics three months after heart transplantation. J Heart Transplant 1989; 8:241-3.

Sweeney MS, Lammermeier DE, Frazier OH et al. Extension of donor criteria in cardiac transplantation: Surgical risk versus supply-side economics. Ann Thorac Surg 1990; 50:7-11.

Sethi GK, Lanauze P, Rosado LJ et al. Clinical significance of weight difference between donor and recipient in heart transplantation. J Thorac Cardiovasc Surg 1993; 106:444-8.

Morley D, Boigon M, Fesniak H et al. Posttransplantation hemodynamics and exercise function are not affected by body-size matching of donor and recipient. J Heart Lung Transplant 1993; 12:770-8.

Mather PJ, Jeevanandam V, Eisen HJ et al. Functional and morphologic adaptation of undersized donor hearts after transplantation. J Am Coll Cardiol 1995; 26:737-42.

Blackbourne LH, Tribble CG, Langenburg SE et al. Successful use of undersized donors for orthotopic heart transplantation—with a caveat. Ann Thorac Surg 1994; 57:1472-6.

Fullerton DA, Gundry SR, Alonso de Begona J et al. The effects of donor-recipient size disparity in infant and pediatric heart transplantation. J Thorac Cardiovasc Surg 1992; 104:1314-9.

Bailey LL, Gundry SR, Razzouk AJ et al. Bless the babies: One hundred fifteen late survivors of heart transplantation during the first year of life. J Thorac Cardiovasc Surg 1993.

Noirclerc M, Shennib H, Giudicelli R et al. Size matching in lung transplantation. J Heart Lung Transplant 1992; 11:S203-8.

Egan TM, Thompson JT, Detterbeck FC et al. Effect of size (mis)matching in clinical double-lung transplantation. Transplantation 1995; 59:707-13. Otulana BA, Mist BA, Scott JP, er al. The effect of recipient lung size on lung physiology after heart-lung transplantation. Transplantation 1989; 48:625-9. Miyoshi S, Schaefers HJ, Trulock EP et al. Donor selection for single and double lung transplantation: Chest size matching and other factors influencing posttransplantation vital capacity. Chest 1990; 98:308-13. UNOS Ad Hoc Donations Committee: Expanded donor criteria: Background and suggestions for kidney donation. Richmond, VA, UNOS, 1992. Lammermeier DE, Sweeney MS, Haupt HE et al. Use of potentially infected donor hearts for cardiac transplantation. Ann Thorac Surg 1990; 50:222-5. Bull DA, Stahl RD, McMahan DL et al. The high risk heart donor: Potential pitfalls. J Heart Lung Transplant 1995; 14:424-8.

Sack FU, Lange R, Mehmanesh H et al. Transferral of extrathoracic donor neoplasm by the cardiac allograft. J Heart Lung Transplant 1997; 16:298-301. Penn I. The problem of cancer in organ transplant recipients: An overview. Transplant Sci 1994; 4:23-.

Weiss L. An analysis of the incidence of myocardial metastases from solid cancers. Br Heart J 1992; 68:501-4.

Houyel L, Petit J, Nottin R et al. Adult heart transplantation: Adverse role of chronic alcoholism in donors on early graft function. J Heart Lung Transplant 1992; 11:1184-7.

Freimark D, Aleksic I, Trento A et al. Hearts from donors with chronic alcohol use: A possible risk factor for death after heart transplantation. J Heart Lung Transplant 1996; 15:150-9.

Smith JA, Bergin PJ, Williams TJ et al. Successful heart transplantation with cardiac allografts exposed to carbon monoxide poisoning. J Heart Lung Transplant 1992; 11:698-700.

Shennib H, Adoumie R, and Fraser R. Successful transplantation of a lung allograft from a carbon monoxide-poisoning victim. J Heart Lung Transplant 1992; 11:68-71.

Iberer F, Konigsrainer A, Wasler A et al. Cardiac allograft harvesting after carbon monoxide poisoning. Report of a successful orthotopic heart transplantation. J Heart Lung Transplant 1993; 12:499-500.

Koerner MM, Tenderich G, Minami K et al. Extended donor criteria. Use of cardiac allografts after carbon monoxide poisoning. Transplantation 1997; 63:1358-60.

Karwande SV, Hopfenbeck JA, Renlund DG et al. An avoidable pitfall in donor selection for heart transplantation. J Heart Lung Transplant 1989; 8:422-4. Baldwin JC, Anderson JL, Boucek MM et al. Twenty-fourth Bethesda Conference: Cardiac Transplantation. Task force 2: Donors guidelines. J Am Coll Cardiol 1993; 22:15-22.

Freimark D, Czer LSC, Admon D et al. Donors with a history of cocaine use: Effect on survival and rejection frequency after heart transplantation. J Heart Lung Transplant 1994; 13:1138-44.

Robiscek F, Masters TN, Thomley AM et al. Bench coronary cineangiography. A possible way to increase the number of hearts available for transplantation. J Thorac Cardiovasc Surg 1992; 103:490-5.

Thomson DJ, Kostuk W, Pflugfelder P et al. De novo coronary artery grafting in a heart transplant recipient. J Heart Transplant 1988; 7:468-70. Doshi R, Neil-Dwyer G. A clinicopathologic study of patients following a subarachnoid hemorrhage. J Neurosurg 1980; 52:295-301.

Shanlin RJ, Sole MJ, Rahimifar M et al. Increased intracranial pressure elicits hypertension, increased sympathetic activity, electrocardiographic abnormalities and myocardial damage in rats. J AM Coll Cardiol 1988; 12:727-36. Pollick C, Cujec B, Parker S et al. Left ventricular wall motion abnormalities in subarachnoid hemorrhage: An echocardiographic study. J AM Coll Cardiol 1988; 12:600-5.

Kono T, Morita H, Kuroiwa T et al. Left ventricular wall motion abnormalities in patients with subarachnoid hemorrhage: Neurogenic stunned myocardium. J Am Coll Cardiol 1994; 24:636-40.

Novitsky D, Wicomb WN, Cooper DKC et al. Electrocardiographic, hemodynamic and endocrine changes occurring during experimental brain death in the Chacma baboon. J Heart Transplant 1984; 4:63-9.

Novitsky D, Wicomb WN, Cooper DKC et al. Prevention of myocardial injury during brain death by total cardiac sympathectomy in the Chacma baboon. Ann Thorac Surg 1986; 41:520-4.

Novitsky D, Cooper DKC, Reichart B. Hemodynamic and metabolic responses to hormonal therapy in brain-dead potential organ donors. Transplantation 1987; 43:852-4.

Novitsky D, Cooper DKC, Rose AG et al. Early donor heart failure following transplantation from myocardial injury sustained during brain death. Clin Transplantation 1987; 1:108-13.

Novitsky D, Horak A, Cooper DKC et al. Electrocardiographic and histopatho-logic changes developing during experimental brain death in the baboon. Transplant Proc 1989; 21:2567-9.

Bittner HB, Kendall SWH, Campbell KA et al. A valid experimental brain death organ donor model. J Heart Lung Transplant 1995; 14:308-17. Egan TM, Boychuk JE, Rosato K et al. Whence the lungs? A study to assess suitability of donor lungs for transplantation. Transplantation 1992; 53:420-2. Hsieh AH, Bishop MJ, Kublis PS, et al Pneumonia following closed head injury. Am Rev Respir Dis 1992; 146:290-4.

Cooper JD. The lung donor: Special considerations. Transplant Proc 1988; 20:17-18.

Egan TM, Kaiser LR, Cooper JD. Lung transplantation. Curr Probl Surg 1989; 26:673-752.

Griffith Clin Chest Med 1989.

Potter CDO, Wheeldon DR, Biol MI et al. Functional assessment and management of heart donors: A rationale for characterization and a guide to therapy. J Heart Lung Transplant 1995; 14:59-65.

Pennefather SH, Bullock RE, Dark JH. The effect of fluid therapy on alveolar arterial oxygen gradient in brain-dead organ donors. Transplantation 1993; 56:1418-22.

Novitsky D, Cooper DKC, Chaffin JS et al. Improved cardiac allograft function following triiodothyronine therapy to both donor and recipient. Transplantation 1990; 49:311-16.

Goarin JP, Cohen S, Riou B et al. The effects of triiodothyronine on hemody-namic status and cardiac function in potential heart donors. Anesth Analg 1996; 83:41-7.

Diabetes 2

Diabetes 2

Diabetes is a disease that affects the way your body uses food. Normally, your body converts sugars, starches and other foods into a form of sugar called glucose. Your body uses glucose for fuel. The cells receive the glucose through the bloodstream. They then use insulin a hormone made by the pancreas to absorb the glucose, convert it into energy, and either use it or store it for later use. Learn more...

Get My Free Ebook


Post a comment